Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 17/20 | 0.77 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.77 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | ATXN2 | Q99700 | 13/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | ABAT | P80404 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21322972 | 1.00 | ENPP2 (0.77) | ENPP2DGAT2CA2ATXN2MAPK8 | |
| SCHEMBL16962686 | 1.00 | ENPP2 (0.77) | ENPP2DGAT2CA2ATXN2MAPK8 | |
| SCHEMBL16963535 | 1.00 | ENPP2 (0.77) | ENPP2DGAT2CA2ATXN2MAPK8 | |
| SCHEMBL16759782 | 0.95 | ENPP2 (0.69) | ENPP2DGAT2CA2ATXN2MAPK8 | |
| SCHEMBL16962381 | 0.94 | ENPP2 (0.69) | ENPP2DGAT2CA2ATXN2MAPK8 | |
| SCHEMBL16962382 | 0.94 | ENPP2 (0.69) | ENPP2DGAT2CA2ATXN2MAPK8 | |
| SCHEMBL16962380 | 0.94 | ENPP2 (0.69) | ENPP2DGAT2CA2ATXN2MAPK8 | |
| SCHEMBL21323076 | 0.92 | ENPP2 (0.66) | ENPP2DGAT2CA2ATXN2HTR2A | |
| SCHEMBL16963831 | 0.92 | ENPP2 (0.66) | ENPP2DGAT2CA2ATXN2HTR2A | |
| SCHEMBL21323293 | 0.91 | ENPP2 (0.64) | ENPP2DGAT2CA2ATXN2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787459-B2 | Bicyclic compounds as ATX inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20180208602-A1 | NEW BICYCLIC COMPOUNDS AS ATX INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2018-07-26 | — | — | US | disclosed |
| WO-2017050732-A1 | BICYCLIC COMPOUNDS AS ATX INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208602-A1 | NEW BICYCLIC COMPOUNDS AS ATX INHIBITORS | ATXN2, ATXN10, ATXN2L | ENPP2 4/4885DGAT2 2907/4885CA2 3500/4885 |
| US-10787459-B2 | Bicyclic compounds as ATX inhibitors | ATXN2, ATXN10, ATXN2L | ENPP2 4/4885DGAT2 2291/4885CA2 3341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.